Coronavirus Spike Glycoprotein (CoV S) peptide (Cy5)
CoV S
适用: Middle East Respiratory Syndrome Coronavirus (MERS-CoV), SARS Coronavirus (SARS-CoV), SARS Coronavirus-2 (SARS-CoV-2)
宿主: 合成
InhA
3 images
(3 references)-
- 抗原 See all Coronavirus Spike Glycoprotein (CoV S) products
- Coronavirus Spike Glycoprotein (CoV S)
- 宿主
- Middle East Respiratory Syndrome Coronavirus (MERS-CoV), SARS Coronavirus (SARS-CoV), SARS Coronavirus-2 (SARS-CoV-2)
-
资源
- 合成
- 标记
- This Coronavirus Spike Glycoprotein peptide is labelled with Cy5.
- 应用范围
- Inhibition Assay (InhA)
- 序列
- Cy5-SLDQINVTFL DLEYEMKKLE EAIKKLEESY IDLKEL
- 产品特性
- EK1 / Pan-HCoV S Inhibitor - Cy5 Labeled
- 纯度
- ≥ 90 %
- 组件
- Each vial contains 1 nmol of NET labeled peptide.
-
Coronavirus Spike Glycoprotein (CoV S) peptide
CoV S 适用: Middle East Respiratory Syndrome Coronavirus (MERS-CoV), SARS Coronavirus (SARS-CoV), SARS Coronavirus-2 (SARS-CoV-2) 宿主: 合成 InhA
-
- 应用备注
- Optimal working dilution should be determined by the investigator.
- 限制
- 仅限研究用
-
- 状态
- Powder
- 储存条件
- 4 °C
- 储存方法
- Store in dry form in a dark place with temperature 0-5°C.
-
-
: "Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein." in: Cellular & molecular immunology, (2020) (PubMed).
: "Drug treatment options for the 2019-new coronavirus (2019-nCoV)." in: Bioscience trends, Vol. 14, Issue 1, pp. 69-71, (2020) (PubMed).
: "A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike." in: Science advances, Vol. 5, Issue 4, pp. eaav4580, (2019) (PubMed).
-
: "Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein." in: Cellular & molecular immunology, (2020) (PubMed).
-
- 抗原
- Coronavirus Spike Glycoprotein (CoV S)
- 别名
- E2 Peptide, E2 glycoprotein precursor Peptide, S Peptide
- 物质类
- Viral Protein
- 分子量
- 4332
-
You are here:
